ROCKVILLE, Md., May 15 /PRNewswire/ -- Theranostics Health (THX) today announced that it has entered into a three-year master research collaboration agreement with Duke University. This relationship will provide Duke investigators access to the company's core technologies: Laser Capture Microdissection (LCM) and Reverse Phase Protein Microarray (RPMA). The proprietary combination of these technologies provides a powerful mechanism to accurately and reliably measure the aberrant protein signaling and protein molecular networks used by tumor cells obtained directly from a patient's biopsy. This information can be used to investigate patient-specific treatments and individual treatment regimens, and also, to better understand the mechanisms of tumorigenesis in order to discover and develop new, safer and more effective therapies.
According to Dr. Neil Spector, Director of Duke's Translational Research Oncology Program, "those of us at Duke who are going to participate in this umbrella agreement with Theranostics Health are excited about the insight this collaboration may provide on the use of phosphoproteomics to shed light on the complexities of the signaling networks that regulate tumor cell growth, survival, migration/invasion, and resistance to targeted therapies. We are intrigued by the possibility of applying this information to investigate more effective therapies for our patients."
"The future of cancer treatment is personalized, targeted therapies and patient stratification for clinical trials," says Dr. Emanuel Petricoin, CSO of Theranostics Health. "We believe that this research collaboration with Duke, one of the top institutions in the world, will provide an important next step for our company in both research applications at the bench as well as working together with Duke investigators during phase I, II and III clinical trials."
Dr. Danong Chen, President and CEO of Theranostics Health, is equally optimistic about the master research agreement with Duke. "We are very pleased to begin collaboration with a nationally-recognized center of excellence and believe that Duke shares our vision of shaping a new paradigm in disease management. This relationship demonstrates the value of this technology for impacting healthcare delivery."
About Theranostics Health
Theranostics Health, LLC is a privately-held company founded in 2006 and based in Rockville, MD. Its core technology is the proprietary combination of Laser Capture Microdissection (LCM) and Reverse Phase Protein Microarray (RPMA) both developed by the company's co-founders Drs. Lance Liotta and Emanuel Petricoin III. The technology measures the activity of a large number of biomarkers, enabling pharmaceutical companies to accurately profile their drug candidates to more efficiently develop safer, more effective therapeutics. More importantly, it enables physicians to tailor optimized therapies to their patients based on the biomarker profile of each individual patient, providing safer and more effective therapies. Theranostics Health is currently working with 5 of the top 10 global pharmaceutical companies in their drug R&D efforts. For more information please email firstname.lastname@example.org or visit http://www.theranosticshealth.com.
CONTACT: Athanasia Anagnostou, Manager of Corporate Development of
Theranostics Health, LLC, +1-301-251-4443, ext. 112, Cell, +1-703-302-0262
Web site: http://www.theranosticshealth.com/